Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.

M A Rubin1, N R Mucci, J Figurski

  • 1Departments of Pathology, Surgery-Urology Section, University of Michigan, Ann Arbor, MI 48109-0054, USA.

Human Pathology
|August 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

WHO 2022 classification of penile and scrotal cancers: updates and evolution.

Histopathology·2022
Same author

Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells.

Proceedings of the National Academy of Sciences of the United States of America·2021
Same author

Interleukin 13 (IL-13)-regulated expression of the chondroprotective metalloproteinase ADAM15 is reduced in aging cartilage.

Osteoarthritis and cartilage open·2020
Same author

Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy.

Seminars in cancer biology·2020
Same journal

TRPS1 and GATA3 Expression in BRG1/SMARCA4-deficient Malignant Neoplasms.

Human pathology·2026
Same journal

Clinicopathologic and Molecular Characteristics of Acral Melanomas Harboring RARA Fusions.

Human pathology·2026
Same journal

Clinical Impact of Second Opinion Consultation in Bladder Biopsies and Transurethral Resection of Bladder Tumors.

Human pathology·2026
Same journal

Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.

Human pathology·2026
Same journal

Mixed Phenotype Acute Leukemia: Lineage Assignment, Immunophenotypic Classification and Genetic Insights.

Human pathology·2026
Same journal

Chronic myelomonocytic leukemia revisited: A comprehensive review with emphasis on the oligomonocytic subtype.

Human pathology·2026
See all related articles

E-cadherin expression is generally high in prostate tissues, including localized and metastatic cancers. Aberrant E-cadherin expression in localized prostate cancer may transiently decrease, correlating with larger tumor size.

Area of Science:

  • Molecular Biology
  • Oncology
  • Epithelial Biology

Background:

  • E-cadherin is a crucial calcium-dependent cell-adhesion molecule essential for epithelial development and homeostasis.
  • Its aberrant or decreased expression is implicated in prostate carcinoma progression, though findings are controversial.
  • Variations in reported E-cadherin expression necessitate a comprehensive evaluation across diverse prostate tissue types.

Purpose of the Study:

  • To systematically evaluate E-cadherin protein expression in benign prostate tissue, localized prostate cancer, and hormone-refractory metastatic prostate cancer.
  • To investigate the association between E-cadherin expression levels and clinicopathological features of prostate cancer.

Main Methods:

  • Analysis of 1,220 prostate tissue samples, including benign, high-grade prostatic intraepithelial neoplasia (PIN), localized prostate cancer, and metastatic prostate cancer, using high-density tissue microarrays (TMA).

Related Experiment Videos

  • Immunohistochemistry was performed using the HECD-1 antibody to assess membranous E-cadherin staining.
  • E-cadherin expression was categorized as high (normal) or low (aberrant), with aberrant defined as <70% strong membranous staining.

    • Main Results:

    • High E-cadherin expression was prevalent: 87% in benign, 80% in high-grade PIN, 82% in localized prostate cancer, and 90% in hormone-refractory metastatic prostate cancer.
    • Aberrant E-cadherin expression showed a significant association with larger tumor size (P = .01) and a trend toward association with positive surgical margins and higher Gleason score.
    • Metastatic hormone-refractory prostate tumors predominantly exhibited strong E-cadherin expression, with rare cases showing aberrant expression.

    Conclusions:

    • The study indicates a high level of E-cadherin expression across various prostate tissue types, including localized and metastatic cancers.
    • Aberrant E-cadherin expression in localized prostate cancer appears to be transient, with a significant association with larger tumor size.
    • The findings suggest that E-cadherin down-regulation may be a transient event in localized prostate cancer, contrasting with its consistent high expression in metastatic disease.